ducovest

FUSA:F:F-Fidelity UCITS SICAV - Fidelity US Quality Income UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 12.218

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Currency: EUR

Country : Germany

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

 USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

 USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

 USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

 USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

 USD 54.47B
VUSA:F Vanguard Funds Public Limited ..

N/A

 USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

 USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

 USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

N/A

 USD 40.89B
0ZC:F Zscaler Inc

N/A

 USD 37.92B

ETFs Containing FUSA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.78% 83% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.78% 82% B 71% C-
Trailing 12 Months  
Capital Gain 30.66% 84% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.66% 82% B 69% C-
Trailing 5 Years  
Capital Gain 91.38% 93% A 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.38% 93% A 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 15.72% 90% A- 77% C+
Dividend Return 15.72% 88% B+ 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.59% 53% F 84% B
Risk Adjusted Return 124.83% 100% F 99% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike